Impetigo: Diagnosis and treatment

American Family Physician

Volumn 90, Issue 4, 2014, Pages 229-235

  Hartman Adams, Holly ^a   Banvard, Christine ^a   Juckett, Gregory ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFALEXIN; CLINDAMYCIN; COCONUT OIL; COTRIMOXAZOLE; DICLOXACILLIN; DISINFECTANT AGENT; DOXYCYCLINE; FUSIDIC ACID; MACROLIDE; MINOCYCLINE; OZENOXACIN; PLEUROMUTILIN; PSEUDOMONIC ACID; RETAPAMULIN; TEA TREE OIL; TOPICAL ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT;

ALLERGIC GLOMERULONEPHRITIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL ARTHRITIS; BLISTER; CELLULITIS; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG COST; GARLIC; GUTTATE PSORIASIS; HONEY; HUMAN; IMPETIGO; IMPETIGO BULLOSA; LYMPHADENITIS; LYMPHANGITIS; NONHUMAN; OLIVE; OSTEOMYELITIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); SEPTICEMIA; STAPHYLOCOCCAL SCALDED SKIN SYNDROME; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES; DIFFERENTIAL DIAGNOSIS; DISEASE MANAGEMENT; HEALTH; INCIDENCE; INTRADERMAL DRUG ADMINISTRATION; PATHOLOGY; SKIN;

ADMINISTRATION, CUTANEOUS; ANTI-BACTERIAL AGENTS; DIAGNOSIS, DIFFERENTIAL; DISEASE MANAGEMENT; GLOBAL HEALTH; HUMANS; IMPETIGO; INCIDENCE; SKIN;

EID: 84921744462     PISSN: 0002838X     EISSN: 15320650     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Brown J, Shriner DL, Schwartz RA, Janniger CK. Impetigo: an update. Int J Dermatol. 2003;42(4):251-255.
2. Feaster T, Singer JI. Topical therapies for impetigo. Pediatr Emerg Care. 2010;26(3):222-227, quiz 228-231.
3. McCaig LF, McDonald LC, Mandal S, Jernigan DB. Staphylococcus aureus-associated skin and soft tissue infections in ambulatory care. Emerg Infect Dis. 2006; 12(11):1715-1723.
4. Cole C, Gazewood J. Diagnosis and treatment of impetigo. Am Fam Physician. 2007;75(6):859-864.
5. Hochedez P, Canestri A, Lecso M, Valin N, Bricaire F, Caumes E. Skin and soft tissue infections in returning travelers. Am J Trop Med Hyg. 2009;80(3):431-434.
6. Bangert S, Levy M, Hebert AA. Bacterial resistance and impetigo treatment trends: a review. Pediatr Dermatol. 2012;29(3):243-248.
7. Luby SP, Agboatwalla M, Feikin DR, et al. Effect of handwashing on child health: a randomised controlled trial. Lancet. 2005;366(9481):225-233.
8. Koning S, van der Sande R, Verhagen AP, et al. Interventions for impetigo. Cochrane Database Syst Rev. 2012; (1):CD003261.
9. Amagai M, Yamaguchi T, Hanakawa Y, Nishifuji K, Sugai M, Stanley JR. Staphylococcal exfoliative toxin B specifically cleaves desmoglein 1. J Invest Dermatol. 2002;118(5):845-850.
10. Hsu S, Halmi BH. Bockhart's impetigo: complication of waterbed use. Int J Dermatol. 1999;38(10):769-770.
11. George A, Rubin G. A systematic review and meta-analysis of treatments for impetigo. Br J Gen Pract. 2003;53(491):480-487.
12. Silverberg N, Block S. Uncomplicated skin and skin structure infections in children: diagnosis and current treatment options in the United States. Clin Pediatr (Phila). 2008;47(3):211-219.
13. Ilyas M, Tolaymat A. Changing epidemiology of acute post-streptococcal glomerulonephritis in Northeast Florida: a comparative study. Pediatr Nephrol. 2008; 23(7):1101-1106.
14. Weinberg JM, Tyring SK. Retapamulin: an antibacterial with a novel mode of action in an age of emerging resistance to Staphylococcus aureus. J Drugs Dermatol. 2010;9(10):1198-1204.
15. Stevens DL, Bisno AL, Chambers HF, et al.; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft-tissue infections [published corrections appear in Clin Infect Dis. 2006;42(8):1219 and Clin Infect Dis. 2005;41(12):1830]. Clin Infect Dis. 2005;41(10):1373-1406.
16. Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. N Engl J Med. 1996;334(4):240-245.
17. Koning S, van Suijlekom-Smit LW, Nouwen JL, et al. Fusidic acid cream in the treatment of impetigo in general practice: double blind randomised placebo controlled trial. BMJ. 2002;324(7331):203-206.
18. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52(3):285-292.
19. Altabax (retapamulin) ointment [package insert]. Research Triangle Park, N.C.: GlaxoSmithKline; 2010. https://www.gsksource.com/gskprm/en/US/adirect/gskprm?cmd=ProductDetailPage&product_id=132084 3776888&featureKey=603182. Accessed May 5, 2014.
20. Yan K, Madden L, Choudhry AE, Voigt CS, Copeland RA, Gontarek RR. Biochemical characterization of the interactions of the novel pleuromutilin derivative retapamulin with bacterial ribosomes. Antimicrob Agents Chemother. 2006;50(11):3875-3881.
21. Landrum ML, Neumann C, Cook C, et al. Epidemiology of Staphylococcus aureus blood and skin and soft tissue infections in the US military health system, 2005-2010. JAMA. 2012;308(1):50-59.
22. Ruby RJ, Nelson JD. The influence of hexachlorophene scrubs on the response to placebo or penicillin therapy in impetigo. Pediatrics. 1973;52(6):854-859.
23. Christensen OB, Anehus S. Hydrogen peroxide cream: an alternative to topical antibiotics in the treatment of impetigo contagiosa. Acta Derm Venereol. 1994;74(6): 460-462.
24. Martin KW, Ernst E. Herbal medicines for treatment of bacterial infections: a review of controlled clinical trials. J Antimicrob Chemother. 2003;51(2):241-246.
25. Sharquie KE, al-Turfi IA, al-Salloum SM. The antibacterial activity of tea in vitro and in vivo (in patients with impetigo contagiosa). J Dermatol. 2000;27(11):706-710.
26. Caelli M, Porteous J, Carson CF, Heller R, Riley TV. Tea tree oil as an alternative topical decolonization agent for methicillin-resistant Staphylococcus aureus. J Hosp Infect. 2000;46(3):236-237.
27. Foamix's minocycline foam-100% effective in impetigo phase II clinical trial with no side effects. 80% improved significantly after 3 days of treatment. March 14, 2012. http://www.foamix.co.il/news.asp?nodeID= 515&itemID=2. Accessed April 2, 2014.
28. Ferrer successfully completes a phase III clinical trial in adult and paediatric patients with impetigo for novel antibacterial compound Ozenoxacin. June 5, 2013. http://www.drugs.com/clinical_trials/ferrer-successfully-completes-phase-i-clinical-trial-adult-paediatric-patients-impetigo-novel-15683.html. Accessed May 8, 2014.